Marker Therapeutics, Inc. announced that on April 27, 2023, Peter Hoang informed the Board of his resignation as Chief Executive Officer, effective May 1, 2023. Mr. Hoang previously served as Senior Vice President of Business Development and Strategy at Bellicum Pharmaceuticals from 2014 to 2017 and as the Managing Director of Innovations at The University of Texas MD Anderson Cancer Center from 2012 to 2014. Mr. Hoang earned a B.A. from Yale University and an M.B.A. from the Anderson School of Management at the University of California, Los Angeles.

Juan Vera, M.D.,age 43, will begin service as Chief Executive Officer effective May 1, 2023. He joined the Board in October 2018 and previously served as its Chief Operating Officer from November 2021 to April 2023 and previously served as its Chief Scientific Officer from October 2018 to April 2023. Dr. Vera is a co-inventor of the multi-tumor associated antigen technology and co-founder of its predecessor, Marker Cell Therapy, Inc. Dr. Vera has held various positions at the Center for Cell and Gene Therapy at Baylor College of Medicine, most recently as an Associate Professor from 2015 to present.

Dr. Vera is also a co-founder of AlloVir, Inc. where he has served as a member of the board of directors since 2014 and previously served as its Chief Product Development Officer from 2014 to June 2020. Dr. Vera received the Idea Development Award from the Department of Defense and Mentored Research Scholar Award from the American Cancer Society. Dr. Vera earned an M.D. from the University El Bosque in Bogota, Colombia.

The Board believes that Dr. Vera's extensive scientific and medical experience, including as the co-inventor of the multi-tumor associated antigen technology, qualifies him to serve on the Board.